Navigation Links
Metabolic Solutions Development Company Receives $773,000 From the Alzheimer's Drug Discovery Foundation to Fund Phase 2a Trial
Date:7/6/2011

KALAMAZOO, Mich., July 6, 2011 /PRNewswire/ -- Metabolic Solutions Development Company (MSDC), a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced today that it has received a $773,000 grant from the Alzheimer's Drug Discovery Foundation (ADDF) to conduct a pilot Phase 2a trial of MSDC-0160, MSDC's pioneer compound for the treatment of metabolic diseases associated with altered mitochondrial function.

"This funding from ADDF enables us to take an important step in the search for a new treatment for Alzheimer's disease," said Jerry Colca, president and chief scientific officer of MSDC.  "MSDC-0160 is a novel insulin sensitizer that modulates mitochondrial metabolism.  Growing evidence suggests that loss of mitochondrial function and decline in brain glucose metabolism could be a contributing cause of Alzheimer's disease.  This study will help us determine if MSDC-0160 affects glucose utilization in specific regions of the brain and determine the feasibility of conducting future large-scale clinical studies in patients with mild Alzheimer's disease."

The double-blind, placebo-controlled study will involve patients age 55-85 who have been diagnosed with mild Alzheimer's disease.  Up to 50 patients will be randomized to receive either MSDC-0160 (150 mg) or placebo once daily for 90 days.  The effects of MSDC-0160 on brain glucose utilization (measured by FDG-PET) and the safety profile of the compound will be analyzed in addition to global cognitive function.  The study will be performed at Rush University Medical Center in Chicago. The principal investigator is Raj C. Shah, M.D., medical director of the Rush Memory Clinic at the Rush Alzheimer's Disease Center. Analysis of brain glucose utilization will be performed in collaboration with the innovative imaging company Abiant, Inc.

The current funding follows a $100,000 grant from the ADDF in 2009 that supported preclinical research, conducted in collaboration with Douglas Feinstein, Ph.D. of the Jesse Brown VA Medical Center and the University of Illinois at Chicago, which demonstrated positive effects of MSDC-0160 in a mouse model of Alzheimer's disease.

"We are very enthusiastic about MSDC's novel compound as a potential new treatment for Alzheimer's disease," said Howard Fillit, MD, ADDF's executive director. "Our ongoing relationship with the company further reinforces the ADDF's commitment to venture philanthropy as a catalyst for the acceleration of new drugs to prevent, treat and, ultimately, cure Alzheimer's disease."

MSDC-0160 also is currently being studied in patients with type 2 diabetes. A 90-day, Phase 2b study involving approximately 330 patients at 26 sites throughout the United States was launched in September 2010.

About Metabolic Solutions Development Company (MSDC)

Metabolic Solutions Development Company (www.msdrx.com) is a drug discovery and development company exploiting novel molecular targets to develop new therapies for metabolic diseases associated with altered mitochondrial function, especially insulin resistance and type 2 diabetes. The company has raised nearly $50 million in support of the development of its pioneer and lead products, MSDC-0160 (currently in Phase 2b) and MSDC-0602 (currently in Phase 2a), which are novel insulin sensitizers that selectively modulate mitochondrial control of certain metabolic-signaling and nutrient-sensing pathways resulting in improved insulin action without fluid retention or weight gain.  Founded in 2006 by former Upjohn Company researchers Jerry Colca, Ph.D. and Rolf Kletzien, Ph.D., MSDC is headquartered in Kalamazoo, Michigan.    

About the Alzheimer's Drug Discovery Foundation

The Alzheimer's Drug Discovery Foundation (ADDF) is the only non-profit organization whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $45 million to fund over 325 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 18 countries.  For more information about the ADDF, please visit www.alzdiscovery.org.

CONTACT:
Tyler Lecceadone
SeyferthPR
1-800-435-9539
lecceadone@seyferthpr.com


'/>"/>
SOURCE Metabolic Solutions Development Company
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. More Evidence Published That Epidemics of Childhood Obesity, Type 2 Diabetes and Metabolic Syndrome are Linked to Immunization
2. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
3. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
4. Atherotech Unveils New Cardiometabolic Test Panels
5. Poxel SAS Set up to Find Innovative Solutions for Metabolic Diseases Management
6. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
7. Bariatric Advantage to Attend American Society of Metabolic and Bariatric Surgery (ASMBS) Conference
8. Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs
9. Max Institute of Minimal Access, Metabolic & Bariatric Surgery Accredited as an International Centre of Excellence for Minimal Invasive Surgery
10. PerkinElmer Expertise and Solutions Integral to Food Safety Monitoring for the Beijing Games : Methods, Applications Expertise and Instrumentation Deployed in Mobile Laboratory
11. StollerUSA Launches Bio-Forge.com to Offer Solutions for Crops Under Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan 19, 2017 Research and Markets ... has announced the addition of the ... - Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future market ... 2025, using estimated market values as the base numbers ...
(Date:1/19/2017)... AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), ... and a majority-owned subsidiary of Intrexon Corporation (NYSE: ... listing of its common shares on the NASDAQ Stock ... "AquaBounty,s listing on NASDAQ represents an important milestone ... the U.S. markets as we advance plans for commercial ...
(Date:1/19/2017)... NEW YORK , Jan. 18, 2017 /PRNewswire/ ... expected to reach USD 92.9 billion by 2025, ... Research, Inc. Pharmaceutical industry has been adaptive of ... functions as early as 2002. Among the services ... the forerunners. For instance, Johnson & Johnson was ...
(Date:1/18/2017)... , January 18, 2017 According to a new market ... Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic and Research ... to reach USD 739.9 Million by 2021 from USD 557.1 Million in 2016, ... ... MarketsandMarkets Logo ...
Breaking Biology Technology:
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ... e-Government, Public Safety, HealthCare, and Finance sectors announced today that Leaders ... to implement and deploy a community-based supportive services program to reduce ... , further expanding its presence in the state. ... This new program, which is expected ...
(Date:12/16/2016)... DUBLIN , Dec 16, 2016 Research ... Access System Market - Global Forecast to 2021" report to ... ... projected to grow at a CAGR of 14.06% from 2016 to ... 2016, and is projected to reach 854.8 Million by 2021. The ...
(Date:12/15/2016)... 2016 Advancements in biometrics will ... and wellbeing (HWW), and security of vehicles ... passenger vehicles begin to feature fingerprint recognition, ... beat monitoring, brain wave monitoring, stress detection, ... pulse detection. These will be driven by ...
Breaking Biology News(10 mins):